↓ Skip to main content

Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Overview of attention for article published in Drugs, August 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
11 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
107 Mendeley
Title
Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Published in
Drugs, August 2014
DOI 10.1007/s40265-014-0267-8
Pubmed ID
Authors

J. Alexander Viehman, M. Hong Nguyen, Yohei Doi

Abstract

Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Argentina 1 <1%
Unknown 104 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 17%
Researcher 18 17%
Student > Ph. D. Student 17 16%
Student > Bachelor 14 13%
Student > Postgraduate 10 9%
Other 30 28%
Readers by discipline Count As %
Medicine and Dentistry 37 35%
Agricultural and Biological Sciences 18 17%
Biochemistry, Genetics and Molecular Biology 16 15%
Unspecified 12 11%
Immunology and Microbiology 12 11%
Other 12 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2018.
All research outputs
#2,331,437
of 13,232,239 outputs
Outputs from Drugs
#292
of 2,473 outputs
Outputs of similar age
#35,026
of 192,989 outputs
Outputs of similar age from Drugs
#6
of 34 outputs
Altmetric has tracked 13,232,239 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,473 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.